+86 400-682-2521 | order.cn@acrobiosystems.com 注册
登录 | 注册    关注公众号 |  
微信公众号
ACRO百普赛斯_logo Recombinant Proteins iso9001 ISO13485 CNAS
热门搜索：TL1A Hot|GMP细胞因子Hot|FcRn Binding Kit (TR-FRET)New|ADC定点偶联试剂盒
ABCDEFGHIJKLMNOPQRSTUVWXYZ0-9
搜索
 > 【TLR8】

TLR8信息

英文名称：Toll like receptor 8
中文名称：Toll样受体8
靶点别称：
上市药物数量：0
临床药物数量：12
最高研发阶段：临床二期

TLR8产品咨询

* 此表格只用于收集产品需求咨询，所有信息将严格保密。
*
*
*
*
*
*
抗体药
 
细胞治疗
 
基因治疗
 
诊断
 
疫苗
 
化药
 
蛋白及多肽药物
 
神经科学
 
XDC
 
其他
 
ACRO质量管理体系
 
评论(0)
 

TLR8 分子别名

TLR8/CD288/Toll-like receptor 8

TLR8 分子背景

Toll-like receptors (TLRs) sense pathogen-associated molecular patterns originating from invading microorganisms and initiate innate immune responses. Toll-like receptors 8 and 7 (TLR8 and TLR7) are endosomal immune receptors and take a key role in innate and adaptive immunity. As a transmembrane receptor, TLR8 could recognize single-stranded RNA. Activation of TLR8 and TLR7 lead to immune cell stimulation and inflammatory cytokine production, which is normally a protective host response.

TLR8 前沿进展

Synergistic Activity of Second Mitochondrial-Derived Activator of Caspases Mimetic with Toll-like Receptor 8 Agonist Reverses HIV-1-Latency and Enhances Antiviral Immunity
Vlaming, Jansen, de Bree et al
Int J Mol Sci (2025) 26 (6)
Abstract: HIV-1 infection is successfully treated by antiretroviral therapy; however, it is not curative as HIV-1 remains present in the viral reservoir. A strategy to eliminate the viral reservoir relies on the reactivation of the latent provirus to subsequently trigger immune-mediated clearance. Here, we investigated whether the activation of Toll-like receptor 8 (TLR8) or RIG-I-like receptor (RLR) together with the latency reversal agent (LRA) second mitochondrial-derived activator of caspases mimetics (SMACm) leads to HIV-1 reservoir reduction and antiviral immune activation. The TLR8 and RLR agonist elicited a robust pro-inflammatory cytokine response in PBMCs from both PWH and uninfected people. Notably, co-stimulation with SMACm specifically enhanced TLR8 induced pro-inflammatory cytokine as well as CD8 T cell responses. Ex vivo treatment of PBMCs from PWH with SMACm significantly decreased the size of the inducible HIV-1 reservoir, whereas targeting TLR8 or RLR reduced the HIV-1 reservoir in 50% of PWH ex vivo. Although co-stimulation with TLR8/RLR agonists further reduced the HIV-1 reservoir in 25% of PWH ex vivo, effectively inducing antiviral immunity may help eliminate reactivated HIV-1 cells in vivo. Our findings strongly suggest that LRAs can be used in combination with agonists for pattern recognition receptors to reactivate HIV-1 and induce antiviral immunity.
Effect of photodynamic therapy on the expression of toll-like receptor 2, -3, -4, and -8 in the cervical lesions
Dushkin, Maxim, Oxana et al
Photochem Photobiol (2025)
Abstract: Photodynamic therapy (PDT) is a minimally invasive treatment with low systemic toxicity and immunomodulatory effects, increasingly applied in managing HPV-associated cervical lesions. Toll-like receptors (TLRs) are critical in regulating immune responses in cervical pathology, yet their dynamics under PDT remain underexplored. This study investigates the effect of PDT on TLR2, TLR3, TLR4, and TLR8 expression in cervical epithelial cells ex vivo, considering lesion severity. The results reveal that TLR8 exhibited the most significant reduction across all groups 2 h after PDT, with the strongest suppression in patients with invasive cervical cancer. TLR4 expression decreased by 24% in HPV-infected patients and by 71% in those with cervical cancer, highlighting its potential role in modulating the inflammatory microenvironment post-PDT. TLR3 showed hyperexpression in LSIL and suppression in HSIL/CIN III, although changes were not statistically significant (p > 0.05). TLR2 expression remained unchanged, likely due to HPV type variability. These findings demonstrate that PDT effectively reduces hyperexpression of TLR8, TLR4, and TLR3 in early-stage cervical cancer, suggesting their potential as biomarkers for treatment efficacy. Further research incorporating HPV typing and advanced techniques like liquid biopsy is essential to refine our understanding of TLRs in PDT for HPV-associated cervical lesions.© 2025 American Society for Photobiology.
Deciphering aptamer-protein interactions for bovine sperm sorting through in silico and in vitro studies
Singh, Mathur, Kamboj et al
Mol Biol Rep (2025) 52 (1), 300
Abstract: In recent years, aptamers have emerged as versatile molecular tools with promising applications in various fields, including diagnostics and therapeutics. In livestock reproduction, their application holds promise for improving the sorting and identification of X and Y chromosome-bearing sperm cells, which is essential for increasing productivity in the dairy and beef industries.This study utilized seven rounds of Cell-SELEX using bovine X and Y sperm cells to isolate specific aptamers that target these cells. A comprehensive in-silico analysis was conducted to evaluate the binding interactions between the selected aptamer sequences and the differentially expressed plasma membrane proteins of X and Y sperm cells.The analysis identified the aptamer sequences APT1X, APT2X, and APT5X as having the most stable interactions with the X sperm surface proteins TLR8 (Toll-like receptor 8), CLRN3, and TLR7 (Toll-like receptor 7), respectively. APT2Y exhibited a relatively high affinity for the protein SCAMP1, a Y-sperm-specific protein. Aptamer‒protein interactions are characterized by hydrogen bonds and hydrophobic contacts. Notably, APT1X formed the greatest number of hydrogen bonds with the polar residues of TLR8, whereas TLR7-APT5X interactions exhibited the greatest number of hydrophobic contacts.The use of in-silico analysis for evaluating the interaction between candidate aptamer sequences and differentially expressed X and Y bovine sperm proteins provides valuable insights. This approach might facilitate the sorting of bovine X and Y sperm cells, contributing to advancements in livestock reproduction strategies.© 2025. The Author(s), under exclusive licence to Springer Nature B.V.
Showing 1-3 of 1722 papers.
Powered by BizGenius

TLR8临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验

扫一扫关注微信公众号获取ACRO最新资讯

ACROBiosystems百普赛斯生物科技股份有限公司

全国：+86 400-682-2521

北京：010-53681107

上海：021-50850665

海外：+1 800-810-0816

邮箱：（产品订购）order.cn@acrobiosystems.com

邮箱：（技术支持）tech.cn@acrobiosystems.com

邮箱：（廉洁合规）lianjie@acrobiosystems.com

地址：北京经济技术开发区宏达北路8号5号楼4层

新闻订阅

订阅

在线留言

发送
隐私政策 | 法律法规 | 网站地图 | 加入我们
©2017 ACROBiosystems中国 京公网安备 11030102010599号 京ICP备16032159号-1

消息提示

请输入您的联系方式,再点击提交！

确定